NovoCure Limited (NVCR) Earnings
NovoCure Limited is expected to report next earnings on October 29, 2026 (in NaN days), with a consensus EPS estimate of $-0.21. NVCR has beaten EPS estimates in 10 of its last 12 reported quarters (average surprise +26.9% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 23, 2026 | $-0.33 | $-0.13 | +60.8% | $184M | +6.5% |
| Apr 30, 2026 | $-0.51 | $-0.62 | -21.0% | $174M | +3.7% |
| Feb 26, 2026 | $-0.41 | $-0.22 | +46.4% | $174M | +0.4% |
| Oct 30, 2025 | $-0.42 | $-0.33 | +21.4% | $167M | -4.2% |
| Jul 24, 2025 | $-0.39 | $-0.36 | +7.7% | $159M | -0.6% |
| Apr 24, 2025 | $-0.47 | $-0.31 | +34.0% | $155M | +0.4% |
| Feb 27, 2025 | $-0.34 | $-0.61 | -79.4% | $161M | +9.1% |
| Oct 30, 2024 | $-0.34 | $-0.28 | +17.6% | $155M | +1.8% |
| Jul 25, 2024 | $-0.40 | $-0.31 | +22.5% | $150M | +5.1% |
| May 2, 2024 | $-0.43 | $-0.36 | +16.3% | $139M | +2.7% |
| Feb 22, 2024 | $-0.53 | $-0.45 | +15.1% | $134M | +2.0% |
| Oct 26, 2023 | $-0.52 | $-0.46 | +11.5% | $127M | -1.3% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · July 23, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
### Commercial Highlights - Q2 2026 was NovoCure's strongest commercial quarter to date, with record net revenue and active patients on therapy, and meaningful progress toward profitability. - Optune Pax received CE Mark approval for locally advanced pancreatic cancer in the EU, and launch activities including prescriber certification have begun in Germany. - NCCN updated its clinical guidelines to add Optune Maya as a category 2A recommended treatment for eligible patients with non-small cell lung cancer brain metastases, ahead of the pending FDA approval. - Japan's national reimbursement for Optune Lua went into effect in March 2026, and early adoption aligns with management expectations; site-by-site contracting is ongoing, and management expects Japan to become NovoCure's leading Optune Lua market as contracting completes. ### Clinical Development Strategy Updates - NovoCure is shifting its clinical development focus from establishing new indications to strengthening its existing market position and broadening product labels. - Near-term focus is on pancreatic cancer: the company is designing additional sponsored trials to support label expansions for locally advanced and earlier-stage resectable pancreatic cancer, and is in active negotiations with industry partners to run pilot feasibility trials combining TT Fields therapy with RAS inhibitors and other new pancreatic cancer therapies, based on encouraging preclinical data. - An IDE trial for combining TT Fields with the upcoming approved RAS inhibitor Deraxan Rasib is being prepared to generate safety and feasibility data; no registrational metastatic pancreatic cancer trial is planned at this time. - The phase 3 Keynote D58 trial for GBM is on track to complete enrollment by the end of 2026, with top-line data expected approximately two years after enrollment closes. - The LUNR2 phase 3 trial for metastatic non-small cell lung cancer has been restructured to cut total trial costs by approximately $90 million: resources are being reallocated to high-enrollment sites, and the protocol is being amended to reduce required sample size. Cost savings from this restructuring will be redirected to pancreatic cancer clinical programs. ### Financial Operational Highlights - Gross margin improved to 78% in Q2 2026 from 74% in Q2 2025, driven by a $5 million tariff refund and improved manufacturing efficiencies lowering array costs. Mid-70% quarterly gross margins are expected for the remainder of 2026 during the Optune Pax launch phase. - R&D expenses decreased 8% year-over-year to $51 million; G&A expenses decreased 9% year-over-year to $40 million, driven by lower share-based compensation. Sales and marketing expenses increased 8% year-over-year to $62 million, driven by Optune Pax U.S. launch and Optune Lua Japan launch costs. - Net loss for the quarter was $16 million ($0.13 loss per share), down from $40 million in Q2 2025. Adjusted EBITDA was positive $11 million, up from negative $10 million in the year-ago quarter. - Cash and investments totaled $441 million as of June 30, 2026.
Guidance
- Full-year 2026 net revenue guidance was revised upward to a range of $710 million to $725 million, representing 8% to 11% year-over-year growth, up from the prior guidance range of $690 million to $710 million. - Combined full-year 2026 revenue guidance for Optune Lua and Optune Pax is maintained at $20 million to $30 million. - Full-year 2026 adjusted EBITDA guidance was revised upward to a range of $0 to $15 million, meaning the company now expects to achieve adjusted EBITDA breakeven for full-year 2026. - Management expects R&D costs to stay at or below current levels after the LUNR2 trial restructuring, while still supporting the prioritized pancreatic cancer clinical development agenda.
Segment performance
Overall company net revenue in Q2 2026 was $184 million, a 16% year-over-year increase. - OptuneGeo: 4,636 total active patients globally, an 11% year-over-year increase. The segment contributed the majority of net revenue, with 8% year-over-year U.S. active patient growth and double-digit growth in Germany, Japan, and other global markets. - Optune Pax: Generated $1.6 million in Q2 2026 revenue, with 418 prescriptions in the quarter and 285 active patients as of June 30, 2026. - Optune Lua: Generated $5.4 million in Q2 2026 revenue, with 207 total active patients globally. 64 of these active patients were in Japan, following the national reimbursement approval in March 2026. - Optune Maya: Still under FDA review for the treatment of brain metastases from non-small cell lung cancer, with a PDUFA decision expected in Q4 2026; no commercial revenue generated yet.
Risks & headwinds
- Forward-looking statements are inherently uncertain, and actual results may differ materially from projections due to risks and uncertainties described in the company's SEC filings, many of which are outside of management's control. - Optune Pax launch in Germany requires case-by-case reimbursement approval, and slower-than-expected uptake due to a required prescriber education process could impact near-term revenue in the region. - Optune Lua growth in Japan is currently gated by hospital-by-hospital contracting, which could delay the expected growth trajectory for the segment. - Optune Pax is still in the early launch phase, and conversion rates from prescription to active therapy and repeat prescription rates have not yet stabilized, creating uncertainty around near-term and long-term revenue projections for the segment.
Analyst Q&A
Q: What is driving strong sequential growth for the Optune Pax launch, how much comes from new vs existing prescribers, and is this growth trajectory sustainable in the second half of 2026?
A: Management notes Q1 only had one month of Optune Pax commercial activity, so the large sequential growth from Q1 to Q2 is partially a statistical artifact. The launch has seen broad adoption across both community and academic practices, with roughly half of prescribers already becoming repeat prescribers, and half only having prescribed once to date. The near-term priority for the second half of 2026 is to increase the share of repeat prescribers and integrate Optune Pax into routine clinical practice.
Q: Why is the planned TT Fields + RAS inhibitor trial only an IDE safety/feasibility trial, not a registrational trial, and what preclinical evidence supports the combination?
A: Management states the fastest path to generate clinical data for the combination after Deraxan Rasib's upcoming FDA approval is an IDE trial focused on safety and feasibility, as both modalities are new. Preclinical data shows TT Fields downregulates a proliferation regulator downstream of the RAS pathway, producing synergistic effects when combined with KRAS inhibitors, results that have been independently replicated by the Mayo Clinic. There is strong clinical interest from KOLs to answer how to use the two therapies together, so the priority is to generate data as quickly as possible.
Q: Why is the high end of the updated full-year 2026 revenue guidance roughly equal to Q2 2026's absolute revenue, rather than implying continued sequential growth?
A: Q2 2026 included $3 million in one-time revenue items, and was an exceptional quarter that outperformed prior periods, with very strong 8% year-over-year U.S. active patient growth for OptuneGeo that is not expected to be repeated every quarter. Management confirmed they are focused on achieving a full-year result toward the upper end of the updated guidance range.
Q: What is early real-world feedback from Optune Pax patients and prescribers, and will combination trials with RAS inhibitors also include the locally advanced setting?
A: Management confirmed combination activity with RAS inhibitors is planned for both metastatic (via the IDE trial) and locally advanced/earlier-stage pancreatic cancer, alongside other innovative new compounds. Early real-world feedback confirms the 6-month improvement in pain-free survival observed in the Panova3 trial has meaningful clinical impact, with patients reporting reduced pain that aligns with the trial data. The company's care team has also successfully supported a diverse range of patients with varying levels of disability from their disease and concurrent treatment.